RaviKAmaravadiMD

PubMed

• Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
  Axfors, C., Schmitt, A., Janiaud, P., Van't Hooft, J., Abd-Elsalam, S., Abdo, E., Abella, B., Akram, J., Amaravadi, R., Angus, D., Arabi, Y., Azhar, S., Baden, L., Bak...> ;Nature Communications. 2024 Feb 5
• FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.
  Thomas M Anderson, Bryan H Chang, Alexander C Huang, Xiaowei Xu, Daniel Yoon, Catherine G Shang, Rosemarie Mick, Erin Schubert, Suzanne McGettigan, Kristin Kreider, We...> ;Clinical Cancer Research. 2024 Jan 24
• HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation.
  Wei Zhang, Jiegang Yang, Beike Wang, Youtao Lu, Jingbo Yang, Wenqun Zhong, Ziyan Yu, Zhiyuan Qin, Bolin Xiao, Kuiming Wang, Yi Y Ma, Ravi Amaravadi, Meenhard Herlyn, J...> ;Cell Reports. 2023 Nov 28
• 20th Anniversary of the Society for Melanoma Research: Celebrating two decades of progress in melanoma research.
  Ravi Amaravadi, Andrew Aplin, Meenhard Herlyn, Sheri Holmen, Richard White, Jessie Villanueva> ;Pigment Cell & Melanoma Research. 2023 Nov 1
• 4 citations
  Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity.
  Wenqun Zhong, Youtao Lu, Xuexiang Han, Jingbo Yang, Zhiyuan Qin, Wei Zhang, Ziyan Yu, Bin Wu, Shujing Liu, Wei Xu, Cathy Zheng, Lynn M Schuchter, Giorgos C Karakousis,...> ;Cell Reports. 2023 Oct 31
• 1 citations
  Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.
  Hwanhee Hong, Anne Friedland, Mengyi Hu, Kevin J Anstrom, Susan Halabi, John E McKinnon, Ravi Amaravadi, Jorge Rojas-Serrano, Benjamin S Abella, Angélica Margarita Por...> ;BMJ Open. 2023 Jun 16
• 7 citations
  Patient-derived melanoma organoid models facilitate the assessment of immunotherapies.
  Lingling Ou, Shujing Liu, Huaishan Wang, Yeye Guo, Lei Guan, Longbin Shen, Ruhui Luo, David E Elder, Alexander C Huang, Giorgos Karakousis, John Miura, Tara Mitchell, ...> ;Ebiomedicine. 2023 Jun 1
• 5 citations
  Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.
  Payal D Shah, Alexander C Huang, Xiaowei Xu, Robert Orlowski, Ravi K Amaravadi, Lynn M Schuchter, Paul Zhang, Julia Tchou, Tina Matlawski, Amanda Cervini, Joanne Shea,...> ;Cancer Research Communications. 2023 May 1
• 2 citations
  A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
  Charu Aggarwal, Alisha P Maity, Joshua M Bauml, Qi Long, Tomas Aleman, Christine Ciunci, Christopher D'Avella, Melissa Volpe, Evan Anderson, Lisa McCormick Jones, Lova...> ;The Oncologist. 2023 Jul 5
• 15 citations
  Recent advances in targeting autophagy in cancer.
  Vaibhav Jain, Mahendra Pal Singh, Ravi K Amaravadi> ;Trends in Pharmacological Sciences. 2023 May 1
• 6 citations
  Lysosomal lipid peroxidation regulates tumor immunity.
  Monika Bhardwaj, Jennifer J Lee, Amanda M Versace, Sandra L Harper, Aaron R Goldman, Mary Ann S Crissey, Vaibhav Jain, Mahendra Pal Singh, Megane Vernon, Andrew E Apli...> ;The Journal of Clinical Investigation. 2023 Apr 17
• 3 citations
  Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition.
  Vaibhav Jain, Sandra L Harper, Amanda M Versace, Dylan Fingerman, Gregory Schuyler Brown, Monika Bhardwaj, Mary Ann S Crissey, Aaron R Goldman, Gordon Ruthel, Qin Liu,...> ;Cancer Discovery. 2023 Feb 6
• 9 citations
  Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy.
  Evgenii N Tcyganov, Emilio Sanseviero, Douglas Marvel, Thomas Beer, Hsin-Yao Tang, Peter Hembach, David W Speicher, Qianfei Zhang, Laxminarasimha R Donthireddy, Ali Mo...> ;Cancer Cell. 2022 Oct 10
• 2 citations
  Pumping Iron: Ferritinophagy Promotes Survival and Therapy Resistance in Pancreatic Cancer.
  Vaibhav Jain, Ravi K Amaravadi> ;Cancer Discovery. 2022 Sep 2
• 21 citations
  HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8T-cell infiltration into tumors.
  Lei Guan, Bin Wu, Ting Li, Lynn A Beer, Gaurav Sharma, Mingyue Li, Chin Nien Lee, Shujing Liu, Changsong Yang, Lili Huang, Dennie T Frederick, Genevieve M Boland, Guan...> ;Nature Communications. 2022 Jul 14
• 2 citations
  Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy.
  Emily J Anstadt, Brian Chu, Nikhil Yegya-Raman, Xiaoyan Han, Abigail Doucette, Kendra Poirier, Jahan J Mohiuddin, Amit Maity, Andrea Facciabene, Ravi K Amaravadi, Gior...> ;The Oncologist. 2022 Sep 2
• 7 citations
  Clinical trial results show promise of targeting autophagymutant melanoma.
  Ravi K Amaravadi> ;Autophagy. 2022 Jun 1
• 12 citations
  Preclinical platforms to study therapeutic efficacy of human γδ T cells.
  Lingling Ou, Huaishan Wang, Hui Huang, Zhiyan Zhou, Qiang Lin, Yeye Guo, Tara Mitchell, Alexander C Huang, Giorgos Karakousis, Lynn Schuchter, Ravi Amaravadi, Wei Guo,...> ;Clinical and Translational Medicine. 2022 Jun 1
• 6 citations
  Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer.
  Thomas B Karasic, Timothy J Brown, Charles Schneider, Ursina R Teitelbaum, Kim A Reiss, Tara C Mitchell, Ryan C Massa, Mark H O'Hara, Lisa DiCicco, Luis Garcia-Marcano...> ;The Oncologist. 2022 Sep 2
• 22 citations
  BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.
  Janice M Mehnert, Tara C Mitchell, Alexander C Huang, Tomas S Aleman, Benjamin J Kim, Lynn M Schuchter, Gerald P Linette, Giorgos C Karakousis, Sheryl Mitnick, Lydia G...> ;Clinical Cancer Research. 2022 Mar 15
• 40 citations
  Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers.
  Josephine R Giles, Sasikanth Manne, Elizabeth Freilich, Derek A Oldridge, Amy E Baxter, Sangeeth George, Zeyu Chen, Hua Huang, Lakshmi Chilukuri, Mary Carberry, Lydia ...> ;Immunity. 2022 Mar 8
• 37 citations
  ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression.
  Wei Zhang, Wenqun Zhong, Beike Wang, Jiegang Yang, Jingbo Yang, Ziyan Yu, Zhiyuan Qin, Alex Shi, Wei Xu, Cathy Zheng, Lynn M Schuchter, Giorgos C Karakousis, Tara C Mi...> ;Developmental Cell. 2022 Feb 7
• 9 citations
  Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer.
  Jennifer J. Lee, Vaibhav Jain, Ravi K. Amaravadi> ;International Journal of Molecular Sciences. 2021 Nov 17
• 7 citations
  Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance.
  Jianglan Liu, Vito W. Rebecca, Andrew V. Kossenkov, Thomas Connelly, Qin Liu, Alexis Gutierrez, Min Xiao, Ling Li, Gao Zhang, Anastasia Samarkina, Delaine Zayasbazan, ...> ;Cancer Research. 2021 Oct 15
• 529 citations
  Autophagy in major human diseases
  Daniel J. Klionsky, Giulia Petroni, Ravi K. Amaravadi, Eric H. Baehrecke, Andrea Ballabio, Patricia Boya, José Manuel Bravo-San Pedro, Ken Cadwell, Francesco Cecconi, ...> ;The EMBO Journal. 2021 Oct 1
• Join now to see all

Journal Articles

• Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers  
  Matthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine
• Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-cell Populations  
  Zeynep Eroglu, Iman Osman, Theodore S Nowicki, Antoni Ribas, Michael A Davies, Farbod Darvishian, Daniel Y Wang, Douglas B Johnson, Ravi K Amaravadi, Clinical Cancer Research
• Emerging Strategies to effectively target autophagy in cancer  
  Rebecca VW, Amaravadi RK, Oncogene, 1/1/2015
• Autophagy in malignant transformation and cancer progression  
  Galluzzi L, Pietrocola1 F, Bravo-San Pedro JM, Amaravadi RK, Cecconi F, Codogno P, Debnath J, Karantza V, Kumar S, Levine B, Maiuri MC, Martin S, Penninger J, Piacen..., EMBO J, 1/1/2015
• Identification of secreted proteins that reflect autophagy dynamics with tumor cells  
  Krayya A, Piao S, Xu G, Zhang G, Gimotty PG, Xu X, Amaravadi RK, Speicher DW, Autophagy, 1/1/2015
• Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors  
  Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, ..., Clinical Cancer Research, 1/1/2015
• Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers  
  Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ, Oncologist, 1/1/2015
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer  
  Twyman-Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, Xu B, Dada H, Odiorizzi P, Herati R, Mansfield K, Patsch D, Amaravadi RK, Schuchter LM, Ishwa..., Nature, 1/1/2015
• A Phase 1 Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma  
  Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA., Molecular Cancer Therapeutics, 1/1/2015
• Targeting the lysosome in cancer  
  Piao S, Amaravadi RK, Ann Ny Acad Sci, 1/1/2015
• BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth  
  Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis GC, Gangadhar TC, Schuchter LM, Li..., Clin Cancer Res, 1/1/2015
• Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression  
  Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB, European Journal of Cancer, 1/1/2015
• Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma  
  Xu MJ, Dorsey JF, Amaravadi R, Karakousis G, Simone CB 2nd, Xu X, Xu W, Carpenter EL, Schuchter L, Kao GD, Oncologist, 1/1/2015
• miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment  
  Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Xu W, Wei Z, Herlyn M, Yao Y, Zhang L, ..., Pigment Cell and Melanoma Research, 1/1/2015
• Phase I and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in dogs with spontaneously occurring lymphoma  
  Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH, Autophagy, 1/1/2014
• Combined Inhibition of Autophagy and HDAC inhibition: A Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Analysis of Hydroxychloroquine in Combination...  
  Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi R, Davis LE, Mita A, Curiel TJ, Espitia CM, Nawrocki ST, Giles FJ, Carew JS., Autophagy, 1/1/2014
• A Phase I/II Trial of Hydroxychloroquine in Conjunction with RadiationTherapy and Concurrent and Adjuvant Temozolomide in Patients with NewlyDiagnosed Glioblastoma Mul...  
  Myrna R. Rosenfeld, Jeffrey G. Supko, Stuart A. Grossman, Steven Brem, Tom Mikkelson, Daniel Wang, Claire Chang, Janice Hu, Quentin McAfee, Andrea Troxel, Shengfu Pia..., Autophagy, 1/1/2014
• Combined autophagy and proteasome inhibition: Phase I trial of hydroxychloroquine with bortezomib in patients with relapsed refractory multiple myeloma  
  Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner ..., Autophagy, 1/1/2014
• Autophagy Gene Atg16l1 Prevents Lethal T CellAlloreactivity Mediated by Dendritic Cells  
  Hubbard-Lucey V, Shono Y,Maurer K,West ML,Singer NV,Ziegler CG, Lezcano, C, Motta AC,Schmid K,Levi SM,Murphy GF,Liu C,Winkler JD,Amaravadi JK,Rogler G,Dickinson AM,Hol..., Immunity, 1/1/2014
• Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma  
  Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amavaradi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS., Pigement Cell and Melanoma Research, 1/1/2014
• Targeting ER stress induced-autophagy overcomes resistance to BRAF inhibition in melanoma  
  Ma XH, Piao SF, Dey S, Mcafee Q, Karakousis G, Villaneuva J , Hart LS, Levi S, Hu J, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M,..., Journal of Clinical Investigation, 1/1/2014
• Ocular Toxicity in BRAF Mutant Melanoma Patients Treated With Vemurafenib  
  Choe, C, Mcarthur GA, Yang M, Caro I, Kempen JH, Amaravadi RK, Am J Ophthalmology, 1/1/2014
• Autophagy: a targetable linchpin of cancer cell metabolism  
  Robert Leone, Ravi Amaravadi, Trends in Endocrinology and Metabolism Cell Press, 1/24/2013
• The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells  
  Krepler C, Chunduru SK, Halloran MB, He X, Xiao M,Vultur A, Villanueva J, Mitsuuchi Y, Neiman EM, Benetatos C, Nathanson KL, Amaravadi RK, Pehamberger H, mckinlay M, H..., Clinical Cancer Research, 1/1/2013
• A Phase II trial of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma  
  Ascierto PA, Minor D, Ribas A, Lebbe C, Siegfried C, Arya N, Guckert M, Schadendorf D, Kefford R, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim K, Martin A..., Journal of Clinical Oncology, 1/1/2013
• Join now to see all

Books/Book Chapters

• Lysosomes, basic mechanisms and roles in disease and drug development. 
  Chapter: Targeting autophagy in cancer therapy. 
  Willis FBEditors: Xiaohong Ma, Shengfu Piao, Quentin Mcafee, Ravi Amaravadi.John Wiley and Sons2014
• Cell Death Signaling in Cancer Biology 
  Chapter: The role of autophagy in drug resistance and potential for therapeutic targeting. Chapter 14 
  Page 87 - 116Editors: Rangwala R, Amaravadi RK.Springer2013

Abstracts/Posters

• Mouse models address key concerns about autophagy inhibition for cancer therapy.
  Amaravadi RK, Debnath J, Cancer Discovery, 1/1/2014
• NRAS and BRAF mutations in atypical melanocytic lesions arising in melanoma patients treated with vemurafenib.
  Emily Y. Chu, Melissa Wilson, Joseph Sobanko, Christopher Miller, EunRan Suh, Wei Xu, Richard Letrero, Rosalie Elenitsas, Giorgos Karakousis, Xiao wei Xu, David Elder,..., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2013
• Gamma knife stereotactic radio-surgery and BRAF inhibition in metastatic melanoma
  Melissa Wilson, John Y Lee, Michelle Alonso-Basanta, Wei Xu, Suzanne McGettigan, Lynn Mara Schuchter, Ravi K. Amaravadi, Tara C. Gangadhar, J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2013
• Clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) and irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer: Phase 2 results
  N. Senzer, P. LoRusso, L. Martin, R. Schilder, R. Amaravadi, K. Papadopoulos, E. Segota, D. Weng, M. Graham, A. Adjei, J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2013
• Efficacy, Safety and Pharmacokinetics of a new formulation of the BRAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib from Part D of a Phase ...
  R. Amaravadi, R. Kudchadkar, R. Gonzalez, D. Lawrence, J. Sosman, J.R. Infante, A. Daud, R. F. Kefford, J. Cebon, W. Sharfman, L. Schuchter, P. Boasberg, K. Lewis, K...., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2013
• PUMA: a puzzle piece in chloroquine's antimelanoma activity.
  Amaravadi RK, Journal of Investigative Dermatology, 1/1/2013
• Autophagy and tumor cell invasion.
  Amaravadi RK, Cell Cycle, 1/14/2012
• Guidelines for the use and interpretation of assays for monitoring autophagy.
  Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S..., Autophagy, 1/1/2012
• Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens.
  Gerald J. Fetterly, Biao Liu, Neil N. Senzer, Ravi K. Amaravadi, Russell J. Schilder, Lainie P. Martin, Patricia LoRusso, Kyriakos P. Papadopoulos, Alex A. Adjei, Patr..., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2012
• Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel.
  Muralidhar Beeram, Amita Patnaik, Ravi K. Amaravadi, Naomi B. Haas, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Lon S. Smith, Kathleen Harlacker, Guillermo Espino, M..., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2012
• MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel.
  Muralidhar Beeram, Amita Patnaik, Ravi K. Amaravadi, Naomi B. Haas, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Lon S. Smith, Kathleen Harlacker, Guillermo Espino, M..., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2012
• Lys05: a new lysosomal autophagy inhibitor.
  Amaravadi RK, Winkler JD, Autophagy, 1/1/2012
• Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM).
  K. B. Kim, K. T. Flaherty, P. B. Chapman, J. A. Sosman, A. Ribas, G. A. McArthur, R. K. Amaravadi, R. J. Lee, K. B. Nolop, I. Puzanov, Journal of Clinical Oncology, 1/29/2011
• A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma t...
  L. A. Fecher, Y. McGrath, D. D. Williams, N. J. Hassan, M. Kalos, L. M. Schuchter, R. K. Amaravadi, A. Chew, E. A. Veloso, B. J. Czerniecki, G. Karakousis, G. P. Linet..., Journal of Clinical Oncology, 1/29/2011
• Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.
  W. H. Sharfman, F. S. Hodi, D. P. Lawrence, K. T. Flaherty, R. K. Amaravadi, K. B. Kim, R. Dummer, S. Gobbi, I. Puzanov, J. A. Sosman, K. Dohoney, L. P. Lam, S. Kakar,..., Journal of Clinical Oncology, 1/29/2011
• Cancer. Autophagy in tumor immunity.
  Amaravadi, Ravi K, Science, 1/16/2011
• Phase 1 study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics, and antitum...
  Ravi K. Amaravadi, Russell J. Schilder, Grace K. Dy, Wen W. Ma, Gerald J. Fetterly Jr., David E. Weng, Martin A. Graham, Jennifer M. Burns, Srinivas K. Chunduru, Steph..., Proceedings of AACR, 1/1/2011
• Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors.
  Kenneth M. Algazy, Lynn M. Schuchter, Angela M. Demichele, Vaughn J. David, Drew A. Torigian, Claire Y. Chang, Maryann Redlinger, Lisa E. Davis, Peter J. O'Dwyer, Ravi..., Proceedings of the American Association for Cancer Research Annual Meeting, 1/1/2011
• Combining chemotherapy with autophagy inhibition: Phase I trial of dose-intense temozolomide and hydroxchloroquine in patients with advanced solid tumors
  Leslie A. Fecher, Lynn M. Schuchter, Tracey Evans, Claire Y. Chang, Maryann Gallagher, Amy Kramer, Peter J. O'Dwyer, Ravi K. Amaravadi, Proceedings of the American Association for Cancer Research annual meeting, 1/1/2011
• Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel.
  D. W. Rasco, A. Patnaik, R. K. Amaravadi, K. P. Papadopoulos, N. B. Haas, A. W. Tolcher, M. Beeram, K. Harlacker, M. A. Drouin, M. Tawashi, J. Wang, A. Karam, C. R. Ma..., Journal of Clinical Oncology, 1/1/2011
• Prolonged responses to vemurafenib in patients with BRAFV600 mutant melanoma with low tumor burden at baseline.
  Amaravadi R, Kim K, Flaherty K, Chapman P, Puzanov I, Sosman J, Ribas A, Lee R, Nolop K, McArthur G, Society for Melanoma Research annual meeting, 1/1/2011
• Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxychloroquine in patients with advanced solid tumors (dose escalation) and me...
  Amaravadi RK, Rangwala R, MCafee QM, Fecher L, Chang C, Torigian D, Alavi A, Saboury B, Panosian J, O'Dwyer, PJ, Schuchter, LM, Society for Melanoma Research annual meeting, 1/1/2011
• Therapeutic modulation of autophagy overcomes resistance to BRAF inhibition in BRAF mutant melanoma
  Ma XH, Piao S, Villanueva J, Karakousis G, Shuchter L, Lynch J, Herlyn M, Davies M, Amaravadi RK, Society for Melanoma Research annual meeting, 1/1/2011
• Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloro...
  M. R. Rosenfeld, S. A. Grossman, S. Brem, T. Mikkelsen, D. Wang, S. Piao, L. E. Davis, P. J. O'Dwyer, R. K. Amaravadi, Journal of Clinical Oncology, 1/1/2010
• Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC)
  J. P. Cetnar, M. A. Rosen, D. J. Vaughn, N. B. Haas, A. B. Troxel, H. Song, G. Adluru, K. T. Flaherty, P. J. O'Dwyer, R. K. Amaravadi, Journal of Clinical Oncology, 1/1/2009
• Join now to see all

Lectures

• Targeting the lysosome in brain metastases. 
  Philadelphia, PA - 1/1/2015
• Targeting the lysosome to cripple cancer cell metabolism. 
  Philadelphia, PA - 1/1/2015
• Targeting Autophagy in Cancer 
  University of Arizona Cancer Center, Tucson, AZ - 1/1/2015
• Clinical Trials and Translational Research (EP815) 
  University of Pennsylvania, Philadelphia, PA - 1/1/2015
• Pharmacodynamic and Pharmaockinetic studies in Phase I Clinical Trials 
  University of Pennsylvania, Philadelphia, PA - 1/1/2015
• Chloroquine Derivatives as anti-cancer agents. 
  1/1/2015
• Targeted therapies for metastatic melanoma. 
  1/1/2015
• Targeted therapies for melanoma. 
  1/1/2015
• Advances in Melanoma 
  1/1/2015
• Targeting autophagy to improve cancer therapy. 
  Austin, TX - 1/1/2014
• Autophagy as a resistance mechanism to signaling inhibitors. 
  Philadelphia, PA - 1/1/2014
• Targeting the lysosome for cancer. 
  1/1/2014
• Targeting autophagy in human health and disease. 
  1/1/2014
• Sabotaging self preservation programs in melanoma by blocking autophagy. 
  Pennsylvania State University Melanoma Center, State College, PA - 1/1/2013
• Autophagy Inhibition for Cancer Therapy 
  University of Pittsburgh, Pittsburgh, PA - 1/1/2013
• Credentialing response biomarkers for targeted therapies. 
  Washington, DC - 1/1/2013
• A phase 1 study of birinapant (TL32711) combined with chemotherapies demonstrates tolerability and clinical activity for solid tumor patients. 
  1/1/2013
• From Bench to Bedside and Back 
  1/1/2013
• Molecular Biology of Genomics 
  Abramson Cancer Center of the University of Pennsylvania - 1/27/2012
• Targeting autophagy for cancer therapy. 
  Albert Einstein Cancer Center, Bronx, NY - 1/1/2012
• Targeting autophagy in cancer. 
  Berlin, Germany - 1/1/2012
• Applying Lessons learned from targeting BRAF in melanoma to targeting autophagy in cancer. 
  Knight Cancer Institute, Oregon Health and Science University, Portland, OR - 1/1/2012
• Targeting autophagy in cancer: progress and unanswered questions. 
  Simon Fraser College, Vancouver, British Columbia, Canada - 1/1/2012
• Apoptosis and autophagy in cancer. 
  University of Pennsylvania - 1/1/2012
• Autophagy inhibition in cancer: progress and unanswered questions. 
  Vancouver, British Columbia, Canada - 1/1/2012
• Join now to see all